Agenus Inc. (AGEN)

In May 2025, Agenus announced new data to be presented at ESMO GI 2025 and moved to sell shares of common stock. Analysts lowered expectations for Agenus after its latest results. In June 2025, Agenus entered into a strategic collaboration with Zydus Lifesciences, including the sale of its biologics CMC facilities and granting Zydus an exclusive license to develop and commercialize botensilimab and balstilimab in India and Sri Lanka. Agenus and Noetik also announced a collaboration. In July 2025, Agenus reported that its BOT/BAL combination achieved 42% two-year survival in refractory MSS CRC. In October 2025, Agenus reported that 39% of patients were alive at two years with BOT/BAL across multiple refractory solid tumors at ESMO 2025. In November 2025, Agenus announced its third-quarter 2025 financial results, appointed Dr. José Iglesias as Chief Medical Affairs Officer, and saw its share price increase.

The demand for Agenus, Inc.'s products and services is not typically subject to seasonal fluctuations. Demand is primarily driven by ongoing medical need, the progression of clinical trials, regulatory approvals, and commercialization efforts. The company's revenue streams are influenced by clinical milestones and market adoption of its therapies.

Agenus, Inc. is an American clinical-stage biotechnology company focused on discovering and developing immunotherapies for cancer and infectious diseases. The company operates within the Pharmaceuticals & Biotech sector, specifically in the Biotechnology and Drug Discovery industries. Agenus's core business segments include immune checkpoint antibodies, cancer vaccines, and adjuvants. Its major products and pipeline candidates include immune-modulatory antibodies like botensilimab and balstilimab, adoptive cell therapies, vaccine adjuvants such as QS-21 Stimulon®, and cancer vaccines like the Prophage Series and neoantigen vaccine platforms.

Agenus Inc. is headquartered in Lexington, Massachusetts, United States, with a global clinical operations footprint. It has manufacturing and development facilities in Berkeley, Emeryville, and Vacaville, California. Internationally, Agenus has a presence in Europe, with an office in Cambridge, UK, and subsidiaries in Belgium, Switzerland, and Ireland. In 2025, Agenus sold its CDMO business, including its biologics manufacturing sites in Emeryville and Berkeley, to Zydus Lifesciences, partnering with Zydus to commercialize its molecules in India and Sri Lanka.

Agenus's brand reputation has been shaped by its scientific advancements and strategic collaborations in immuno-oncology. Positive impacts include clinical data and presentations, strategic partnerships with Zydus Lifesciences and Noetik, and a focus on operational efficiency. Potential challenges include earnings misses and stock sales. Overall, Agenus has maintained a reputation as a leader in immuno-oncology innovation.

Agenus Inc. has a diverse ownership structure, with significant institutional and individual holdings. Major institutional shareholders include The Vanguard Group, Inc., Siren, L.L.C., BlackRock, Inc., State Street Global Advisors, Inc., Morgan Stanley, and Geode Capital Management, Llc. Garo H. Armen, the CEO, is a significant individual shareholder. The general public also owns a substantial stake in the company.